Granted Patent
B2
US 12,246,054 · App. 18/599,125 · Granted Mar 11, 2025
Method of treating diseases
Assignee:
Amryt Endo, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Claims (17)
1. A method of treating acromegaly in a subject in whom prior treatment with a somatostatin analog has been shown to be effective and tolerated, the method comprising orally administering to the subject at least one dosage form comprising octreotide, wherein the oral administration provides a mean peak plasma octreotide concentration of about 3.5+/−0.5 ng/ml, wherein the total amount of octreotide orally administered per day is from 40 mg to 80 mg, and wherein the oral administration provides improved control of acromegaly symptoms compared to treatment with an injectable somatostatin analog.
2. The method of claim 1 , wherein the dosage form comprises an oily suspension which is formulated into a capsule.
3. The method of claim 2 , wherein the capsule is enterically coated.
4. The method of claim 1 , wherein the amount of octreotide in each dosage form is 20 mg.
5. The method of claim 1 , wherein the at least one dosage form is orally administered twice a day.
6. The method of claim 1 , wherein at least one dosage form is orally administered in the morning and at least one dosage form is orally administered in the evening.
7. The method of claim 6 , wherein the total amount of octreotide orally administered per day is 40 mg.
8. The method of claim 6 , wherein the total amount of octreotide orally administered per day is 60 mg.
9. The method of claim 6 , wherein the total amount of octreotide orally administered per day is 80 mg.
10. The method of claim 1 , wherein the method is for long-term maintenance therapy in acromegaly patients.
11. The method of claim 7 , wherein if insulin-like growth factor 1 (IGF-1) level of the subject is normal and the subject's clinical signs and symptoms are controlled, or biochemical and symptomatic response level of the subject is maintained by the oral administration of 40 mg daily of octreotide, then the total amount of octreotide orally administered per day is continued at 40 mg.
12. The method of claim 7 , wherein if IGF-1 level of the subject is not normal and the subject's clinical signs and symptoms are not controlled, or biochemical and symptomatic response level of the subject is not maintained by the oral administration of 40 mg daily of octreotide, then the total amount of octreotide orally administered per day is increased to 60 mg.
13. The method of claim 12 , wherein if IGF-1 level of the subject is normal and the subject's clinical signs and symptoms are controlled, or biochemical and symptomatic response level of the subject is maintained by the oral administration of 60 mg daily of octreotide, then the total amount of octreotide orally administered per day is continued at 60 mg daily.
14. The method of claim 12 , wherein if IGF-1 level of the subject is not normal and the subject's clinical signs and symptoms are not controlled, or biochemical and symptomatic response level of the subject is not maintained by the oral administration of 60 mg daily of octreotide, then the total amount of octreotide orally administered per day is increased to 80 mg.
15. The method of claim 1 , wherein the oral administration provides a mean area under the curve of octreotide of about 15+/−4 h·ng/mL.
16. The method of claim 1 , wherein the oral administration controls the growth hormone (GH) level or the IGF-1 level or acromegaly symptoms of the subject.
17. The method of claim 16 , wherein the oral administration provides an in vivo concentration of IGF-1 equal to or less than 1.3 times the upper limit of the age-adjusted normal range (ULN).
Assignments (4)
MERGER AND CHANGE OF NAME
Recorded Jan 7, 2026
From: AMRYT ENDO, INC.; AMYRT PHARMACEUTICALS INC.
To: AMRYT PHARMACEUTICALS INC.
Reel/Frame 073389/0551 →
CHANGE OF ADDRESS
Recorded Oct 16, 2024
From: AMRYT ENDO, INC.
To: AMRYT ENDO, INC.
Reel/Frame 070069/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 16, 2024
From: MAMLUK, RONI; TEICHMAN, SAM L.
To: CHIASMA, INC.
Reel/Frame 068908/0974 →
MERGER
Recorded Oct 16, 2024
From: ACORN MERGER SUB, INC.; CHIASMA, INC.
To: AMRYT ENDO, INC.
Reel/Frame 068908/0982 →
Continuity (9)
Provisional Application
62136012
· Mar 20, 2015
Provisional Application
62111369
· Feb 3, 2015
References Cited (400)
US 3869549A
· Geller
· 1975
[cited by applicant]
US 4156719A
· Sezaki et al.
· 1979
[cited by applicant]
US 4234437A
· Friberg et al.
· 1980
[cited by applicant]
US 4338306A
· Kitao et al.
· 1982
[cited by applicant]
US 4411890A
· Momany
· 1983
[cited by applicant]
US 4485033A
· Kitao et al.
· 1984
[cited by applicant]
US 4489097A
· Stone
· 1984
[cited by applicant]
US 4508828A
· Lindall et al.
· 1985
[cited by applicant]
US 4544500A
· Bittle et al.
· 1985
[cited by applicant]
US 4572915A
· Crooks
· 1986
[cited by applicant]
US 4589881A
· Pierschbacher et al.
· 1986
[cited by applicant]
US 4650665A
· Kronenthal et al.
· 1987
[cited by applicant]
US 4650787A
· Schally et al.
· 1987
[cited by applicant]
US 4839344A
· Bowers et al.
· 1989
[cited by applicant]
US 4871777A
· Breitzke
· 1989
[cited by applicant]
US 4895726A
· Curtet et al.
· 1990
[cited by applicant]
US 4985404A
· Mitchell
· 1991
[cited by applicant]
US 5200192A
· Wimmer
· 1993
[cited by applicant]
US 5206219A
· Desai
· 1993
[cited by applicant]
US 5246716A
· Sedun et al.
· 1993
[cited by applicant]
US 5254331A
· Mausner
· 1993
[cited by applicant]
US 5288492A
· Morris
· 1994
[cited by applicant]
US 5318781A
· Shah et al.
· 1994
[cited by applicant]
US 5354883A
· Isak et al.
· 1994
[cited by applicant]
US 5393738A
· Vonderscher et al.
· 1995
[cited by applicant]
US 5443842A
· Seghizzi et al.
· 1995
[cited by applicant]
US 5462726A
· Lodge
· 1995
[cited by applicant]
US 5491171A
· Nishimura et al.
· 1996
[cited by applicant]
US 5506203A
· Backstrom et al.
· 1996
[cited by applicant]
US 5561115A
· Tenold
· 1996
[cited by applicant]
US 5656289A
· Cho et al.
· 1997
[cited by applicant]
US 5658878A
· Backstrom et al.
· 1997
[cited by applicant]
US 5665384A
· Courteille et al.
· 1997
[cited by applicant]
US 5665711A
· Sakai et al.
· 1997
[cited by applicant]
US 5686488A
· Gamache et al.
· 1997
[cited by applicant]
US 5714477A
· Einarsson
· 1998
[cited by applicant]
US 5726154A
· Baudys et al.
· 1998
[cited by applicant]
US 5738871A
· Story
· 1998
[cited by applicant]
US 5760096A
· Thornfeldt et al.
· 1998
[cited by applicant]
US 5804573A
· Silver
· 1998
[cited by applicant]
US 5827534A
· Fasano
· 1998
[cited by applicant]
US 5840685A
· Fujii et al.
· 1998
[cited by applicant]
US 5853748A
· New
· 1998
[cited by applicant]
US 5858401A
· Bhalani et al.
· 1999
[cited by applicant]
US 5859048A
· Oohashi et al.
· 1999
[cited by applicant]
US 5929030A
· Hamied et al.
· 1999
[cited by applicant]
US 5942237A
· Gizurarson et al.
· 1999
[cited by applicant]
US 6013657A
· Lavon et al.
· 2000
[cited by applicant]
US 6096338A
· Lacy et al.
· 2000
[cited by applicant]
US 6114319A
· Kimura et al.
· 2000
[cited by applicant]
US 6120801A
· Parekh et al.
· 2000
[cited by applicant]
US 6136336A
· Tanaka et al.
· 2000
[cited by applicant]
US 6150333A
· Moreau
· 2000
[cited by applicant]
US 6190702B1
· Takada et al.
· 2001
[cited by applicant]
US 6193986B1
· Sakurada
· 2001
[cited by applicant]
US 6200602B1
· Watts et al.
· 2001
[cited by applicant]
US 6214380B1
· Parekh et al.
· 2001
[cited by applicant]
US 6214792B1
· Simon
· 2001
[cited by applicant]
US 6255502B1
· Penkler et al.
· 2001
[cited by applicant]
US 6284223B1
· Luiken
· 2001
[cited by applicant]
US 6322550B2
· Iga et al.
· 2001
[cited by applicant]
US 6326026B1
· Parekh et al.
· 2001
[cited by applicant]
US 6326360B1
· Kanazawa et al.
· 2001
[cited by applicant]
US 6333046B1
· Sakai et al.
· 2001
[cited by applicant]
US 6365596B1
· Valenti
· 2002
[cited by applicant]
US 6368622B2
· Chen et al.
· 2002
[cited by applicant]
US 6383527B1
· Artman et al.
· 2002
[cited by applicant]
US 6395708B1
· Miller et al.
· 2002
[cited by applicant]
US 6419949B1
· Gasco
· 2002
[cited by applicant]
US 6428813B1
· Akiyama et al.
· 2002
[cited by applicant]
US 6632443B2
· Borowy-Borowski et al.
· 2003
[cited by applicant]
US 6664234B1
· Heintz et al.
· 2003
[cited by applicant]
US 6696413B2
· Fischer et al.
· 2004
[cited by applicant]
US 6710195B2
· Joshi-Hangal et al.
· 2004
[cited by applicant]
US 6720002B2
· Lin et al.
· 2004
[cited by applicant]
US 6770292B2
· Guinez et al.
· 2004
[cited by applicant]
US 6835396B2
· Brynjelsen et al.
· 2004
[cited by applicant]
US 6890961B2
· Li et al.
· 2005
[cited by applicant]
US 7141547B2
· Rosen et al.
· 2006
[cited by applicant]
US 7217431B2
· Holm et al.
· 2007
[cited by applicant]
US 7288520B2
· Chang et al.
· 2007
[cited by applicant]
US 7411039B2
· Thim et al.
· 2008
[cited by applicant]
US 7759312B2
· Kuzma et al.
· 2010
[cited by applicant]
US 8133863B2
· Maggio
· 2012
[cited by applicant]
US 8241670B2
· Ben-Sasson
· 2012
[cited by applicant]
US 8329198B2
· Salama et al.
· 2012
[cited by applicant]
US 8535695B2
· Salama
· 2013
[cited by examiner]
US 8822637B2
· Albert et al.
· 2014
[cited by applicant]
US 8883203B2
· Leonard
· 2014
[cited by applicant]
US 9265812B2
· Mamluk et al.
· 2016
[cited by applicant]
US 9566246B2
· Mamluk et al.
· 2017
[cited by applicant]
US 20010055569A1
· Davis et al.
· 2001
[cited by applicant]
US 20020091623A1
· Daniels
· 2002
[cited by applicant]
US 20020151495A1
· Wolfe et al.
· 2002
[cited by applicant]
US 20020188148A1
· O'Lenick, Jr. et al.
· 2002
[cited by applicant]
US 20030091623A1
· Cumming et al.
· 2003
[cited by applicant]
US 20030095928A1
· McGurk et al.
· 2003
[cited by applicant]
US 20030108610A1
· Flore et al.
· 2003
[cited by applicant]
US 20030125528A1
· Hay et al.
· 2003
[cited by applicant]
US 20030153614A1
· Joshi-Hangal et al.
· 2003
[cited by applicant]
US 20030162695A1
· Schatzberg et al.
· 2003
[cited by applicant]
US 20030166508A1
· Zhang
· 2003
[cited by applicant]
US 20030176379A1
· Raoof et al.
· 2003
[cited by applicant]
US 20040009231A1
· Jackson et al.
· 2004
[cited by applicant]
US 20040097419A1
· Petersen et al.
· 2004
[cited by applicant]
US 20040147599A1
· Gagnon et al.
· 2004
[cited by applicant]
US 20040167205A1
· Joshi-Hangal et al.
· 2004
[cited by applicant]
US 20040185170A1
· Chungi et al.
· 2004
[cited by applicant]
US 20040248901A1
· Lee et al.
· 2004
[cited by applicant]
US 20040253723A1
· Tachas et al.
· 2004
[cited by applicant]
US 20050004002A1
· Desai et al.
· 2005
[cited by applicant]
US 20050112191A1
· Lipari et al.
· 2005
[cited by applicant]
US 20050142225A1
· Kysilka et al.
· 2005
[cited by applicant]
US 20050186277A1
· Gale et al.
· 2005
[cited by applicant]
US 20050209441A1
· Lile
· 2005
[cited by applicant]
US 20050232981A1
· Ben-Sasson
· 2005
[cited by applicant]
US 20050256097A1
· Zhong et al.
· 2005
[cited by applicant]
US 20050287203A1
· Nijs De et al.
· 2005
[cited by applicant]
US 20060002989A1
· Ahmed et al.
· 2006
[cited by applicant]
US 20060014712A1
· Neuman
· 2006
[cited by applicant]
US 20060052404A1
· Rudolph et al.
· 2006
[cited by applicant]
US 20060057185A1
· Akimoto et al.
· 2006
[cited by applicant]
US 20060069055A1
· Dajee et al.
· 2006
[cited by applicant]
US 20060078618A1
· Constantinides et al.
· 2006
[cited by applicant]
US 20060128800A1
· Penney et al.
· 2006
[cited by applicant]
US 20060165809A1
· Guimberteau et al.
· 2006
[cited by applicant]
US 20060188566A1
· Liversidge et al.
· 2006
[cited by applicant]
US 20060189662A1
· Goto et al.
· 2006
[cited by applicant]
US 20060204540A1
· Kuzma et al.
· 2006
[cited by applicant]
US 20060275253A1
· Ushida et al.
· 2006
[cited by applicant]
US 20070004668A1
· Raoof et al.
· 2007
[cited by applicant]
US 20070015694A1
· Chang et al.
· 2007
[cited by applicant]
US 20070021325A1
· Byun et al.
· 2007
[cited by applicant]
US 20070066512A1
· Verhelle et al.
· 2007
[cited by applicant]
US 20070104741A1
· Murty et al.
· 2007
[cited by applicant]
US 20070134319A1
· Zannou et al.
· 2007
[cited by applicant]
US 20070148228A1
· Cumming et al.
· 2007
[cited by applicant]
US 20070185194A1
· Mehta et al.
· 2007
[cited by applicant]
US 20070190139A1
· Zerbe et al.
· 2007
[cited by applicant]
US 20070196464A1
· Cumming et al.
· 2007
[cited by applicant]
US 20070207214A1
· Castan et al.
· 2007
[cited by applicant]
US 20070219131A1
· Ben-Sasson
· 2007
[cited by applicant]
US 20070224142A1
· Swaile et al.
· 2007
[cited by applicant]
US 20070237832A1
· Sackler et al.
· 2007
[cited by applicant]
US 20070237833A1
· Sackler et al.
· 2007
[cited by applicant]
US 20070238707A1
· Leonard
· 2007
[cited by applicant]
US 20070248549A1
· Kuhrts
· 2007
[cited by applicant]
US 20070248668A1
· Michaelis et al.
· 2007
[cited by applicant]
US 20070254954A1
· Sakakibara et al.
· 2007
[cited by applicant]
US 20070259098A1
· Gulian et al.
· 2007
[cited by applicant]
US 20070292512A1
· Leonard et al.
· 2007
[cited by applicant]
US 20080139392A1
· Acosta-Zara et al.
· 2008
[cited by applicant]
US 20080255029A1
· Marks et al.
· 2008
[cited by applicant]
US 20080275001A1
· Cumming et al.
· 2008
[cited by applicant]
US 20090220611A1
· Dargelas et al.
· 2009
[cited by applicant]
US 20090246172A1
· Rothermel et al.
· 2009
[cited by applicant]
US 20090280169A1
· Leonard
· 2009
[cited by applicant]
US 20100028421A1
· Cumming et al.
· 2010
[cited by applicant]
US 20100105627A1
· Salama et al.
· 2010
[cited by applicant]
US 20100151033A1
· Ahlheim et al.
· 2010
[cited by applicant]
US 20100285143A1
· Khedkar et al.
· 2010
[cited by applicant]
US 20110142800A1
· Kidron et al.
· 2011
[cited by applicant]
US 20110257095A1
· Salama et al.
· 2011
[cited by applicant]
US 20120009229A1
· Salama et al.
· 2012
[cited by applicant]
US 20120093886A1
· Salama et al.
· 2012
[cited by applicant]
US 20140188042A1
· Browning
· 2014
[cited by applicant]
US 20150031631A1
· Mamluk et al.
· 2015
[cited by applicant]
US 20150141338A1
· Fujiki et al.
· 2015
[cited by applicant]
US 20150141349A1
· Davis et al.
· 2015
[cited by applicant]
US 20150258179A1
· LaRusso et al.
· 2015
[cited by applicant]
US 20150283147A1
· Proia et al.
· 2015
[cited by applicant]
US 20160158159A1
· Mamluk et al.
· 2016
[cited by applicant]
US 20160193285A1
· Haviv
· 2016
[cited by applicant]
US 20160220628A1
· Mamluk
· 2016
[cited by applicant]
US 20170112938A1
· Mamluk et al.
· 2017
[cited by applicant]
US 20170266183A1
· Koziol
· 2017
[cited by applicant]
US 20190038758A1
· Mamluk et al.
· 2019
[cited by applicant]
US 20190091285A1
· Haviv
· 2019
[cited by applicant]
US 20190298792A1
· Mamluk et al.
· 2019
[cited by applicant]
US 20200390847A1
· Mamluk et al.
· 2020
[cited by applicant]
US 20200397906A1
· Mamluk et al.
· 2020
[cited by applicant]
US 20210052691A1
· Mamluk et al.
· 2021
[cited by applicant]
US 20210077569A1
· Haviv
· 2021
[cited by applicant]
US 20210187079A1
· Mamluk et al.
· 2021
[cited by applicant]
US 20220202911A1
· Teichman et al.
· 2022
[cited by applicant]
US 20220233630A1
· Mamluk et al.
· 2022
[cited by applicant]
US 20220233633A1
· Haviv et al.
· 2022
[cited by applicant]
US 20220339240A1
· Haviv
· 2022
[cited by applicant]
US 20220370621A1
· Mamluk et al.
· 2022
[cited by applicant]
US 20220370622A1
· Mamluk et al.
· 2022
[cited by applicant]
US 20220378867A1
· Mamluk et al.
· 2022
[cited by applicant]
US 20230173034A1
· Mamluk et al.
· 2023
[cited by applicant]
US 20230201302A1
· Haviv et al.
· 2023
[cited by applicant]
US 20240016899A1
· Mamluk et al.
· 2024
[cited by applicant]
US 20240041973A1
· Haviv et al.
· 2024
[cited by applicant]
US 20240050533A1
· Teichman et al.
· 2024
[cited by applicant]
US 20240082343A1
· Mamluk et al.
· 2024
[cited by applicant]
US 20240123024A1
· Haviv et al.
· 2024
[cited by applicant]
CA 2003340A1
· 1990
[cited by applicant]
CA 2044511A1
· 1991
[cited by applicant]
CA 2069760A1
· 1992
[cited by applicant]
CA 2363123A1
· 2000
[cited by applicant]
CA 2563533A1
· 2006
[cited by applicant]
CA 2655273A1
· 2007
[cited by applicant]
CN 1960746A
· 2007
[cited by applicant]
CN 101084016A
· 2007
[cited by applicant]
EP 0204480A3
· 1989
[cited by applicant]
EP 0366277A2
· 1990
[cited by applicant]
EP 0370481A2
· 1990
[cited by applicant]
EP 0480189A1
· 1992
[cited by applicant]
EP 0554767A1
· 1993
[cited by applicant]
EP 1154761A1
· 2001
[cited by applicant]
EP 1424077A1
· 2004
[cited by applicant]
EP 2123255A1
· 2009
[cited by applicant]
EP 2343982A2
· 2011
[cited by applicant]
IE 63119B1
· 1995
[cited by applicant]
IL 252689A
· 2021
[cited by applicant]
JP 2007528388A
· 2007
[cited by applicant]
JP 2010510206A
· 2010
[cited by applicant]
JP 2011503160A
· 2011
[cited by applicant]
JP 2011113487A
· 2011
[cited by applicant]
WO WO8707149A1
· 1987
[cited by applicant]
WO WO9317037A1
· 1993
[cited by applicant]
WO WO9631213A1
· 1996
[cited by applicant]
WO WO9705903A2
· 1997
[cited by applicant]
WO WO0047203A1
· 2000
[cited by applicant]
WO WO0050012A1
· 2000
[cited by applicant]
WO WO0074736A1
· 2000
[cited by applicant]
WO WO0101960A1
· 2001
[cited by applicant]
WO WO03004001A1
· 2003
[cited by applicant]
WO WO03013589A1
· 2003
[cited by applicant]
WO WO03037345A1
· 2003
[cited by applicant]
WO WO03060071A2
· 2003
[cited by applicant]
WO WO2004087052A2
· 2004
[cited by applicant]
WO WO2005000012A1
· 2005
[cited by applicant]
WO WO2005041901A2
· 2005
[cited by applicant]
WO WO2005046642A1
· 2005
[cited by applicant]
WO WO2005087194A1
· 2005
[cited by applicant]
WO WO2005094785A2
· 2005
[cited by applicant]
WO WO2005115333A2
· 2005
[cited by applicant]
WO WO2006013369A2
· 2006
[cited by applicant]
WO WO2006097793A2
· 2006
[cited by applicant]
WO WO2006123360A2
· 2006
[cited by applicant]
WO WO2006127214A1
· 2006
[cited by applicant]
WO WO2007071395A1
· 2007
[cited by applicant]
WO WO2007095091A2
· 2007
[cited by applicant]
WO WO2008066279A1
· 2008
[cited by applicant]
WO WO2008092084A2
· 2008
[cited by applicant]
WO WO2009102443A2
· 2009
[cited by applicant]
WO WO2010032140A2
· 2010
[cited by applicant]
WO WO2011032140A1
· 2011
[cited by applicant]
WO WO2011112576A1
· 2011
[cited by applicant]
WO WO2014049515A1
· 2014
[cited by applicant]
WO WO2016094662A1
· 2016
[cited by applicant]
WO WO2016126830A1
· 2016
[cited by applicant]
WO WO2017127710A1
· 2017
[cited by applicant]
WO WO2023164614A1
· 2023
[cited by applicant]
Sandostatin LAR® Depot ([online] retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021008s018s019lbl.pdf; 1998:17 pages) (Year: 1998).
[cited by examiner]
Adelman et al. “Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment” International Journal of General Medicine (2013) vol. 6, pp. 31-38.
[cited by applicant]
Aliautdin RN., et al., “[Drug delivery to the brain with nanoparticles]”, [Article in Russian] Eksp Klin Farmakol. Mar.-Apr. 2003; 66(2): 65-8, (Abstract), 1 page.
[cited by applicant]
Ansel, H.C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Ed. Lippincott Williams & Wilkins, 1999; pp. 48.
[cited by applicant]
Armstrong, “Cellular Mechanisms of lon Transport in The Small Intestine”, Physiology of the Gastrointestinal Tract, Chapter 45, 2nd Ed., Johnson, ed., Raven Press, New York, 2: 1251-1265, 1987.
[cited by applicant]
Aungst et al., “Enhancement of intestinal absorption of peptides and non-peptides” J. of Controlled Release, vol. 41, pp. 19-31 (1996).
[cited by applicant]
Azziz et al., “Androgen excess disorders in women: polycystic ovary syndrome and other disorders second edition”, Humana Press Inc., 2006, pp. 1-459.
[cited by applicant]
Bernkop-Schnürch, “The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins”, J. Control. Release, 52: 1-16, 1998.
[cited by applicant]
Besson et al. “Sclerotherapy With or Without Octreotide for Acute Variceal Bleeding” The New England Journal of Medicine (1995) vol. 333, No. 9, pp. 555-560.
[cited by applicant]
Biousse et al. “Update on the pathophysiology and management of idiopathic intracranial hypertension”, J Neurol Neurosurg Psychiatry (2012) vol. 83, pp. 488-494.
[cited by applicant]
Caron, P.H., et al., “Efficacy of the New Long-acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly,” The Journal of Clinical Endocrinology & Metabolism, Jan. 1, 2002, vol. 87(1), pp. 99…
[cited by applicant]
Chanson et al. “Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly”, Clinical Endocrinology (2000) vol. 53, pp. 577-586.
[cited by applicant]
Citi, “Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells.” J Cell Biol, 117(1): 169-178 (1992).
[cited by applicant]
Constantinides, et. al., “Formulation and intestinal absorption enhancement evaluation of water-in-oil micro emulsions incorporating medium-chain glycerides.” Pharm. Res., 11(10): 1385-1390 (1994).
[cited by applicant]
Corley, et al., “Octreotide for acute esophageal variceal bleeding: A meta-analysis”, Gastroenterology, 2001; 120: 946-954 (2001 ).
[cited by applicant]
Costa et al. “Octreotide—A Review of its Use in Treating Neuroendocrine Tumours” European Oncology Haematology, (2013) vol. 9, No. 2, pp. 105-109.
[cited by applicant]
“Dad found drug for sick daughter using internet research” The Sentinel, Jul. 22, 2010. 2 pages.
[cited by applicant]
Deftereos et al. “Treatment of idiopathic intracranial hypertension: Is there a place for octreotide?” Cephalalgia (2011) vol. 31, No. 16, pp. 1679-1680.
[cited by applicant]
Delie, “Evaluation of nano- and microparticle uptake by the gastrointestinal tract.” Adv. Drug Del. Rev., 34(1): 221-233 (1998).
[cited by applicant]
Dorkoosh et al. “Peroral Absorption of Octreotide in Pigs Formulated in Delivery Systems on the Basis of Superporous Hydrogel Polymers” Pharmaceutical Research (2002) vol. 19, No. 10 pp. 1532-1536.
[cited by applicant]
Drewe et al. “Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether”, Br. J. Pharmacol. (1993) vol. 108, pp. 298-303.
[cited by applicant]
Duarte et al. “Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies” Journal of Clinical Endocrinology Metabolism (2015) 100(5): 1863-1869; p. 1-8. 8 pages.
[cited by applicant]
Duarte et al. “Impact of clomiphene citrate on IGF-1 and testosterone levels in acromegalic patients non controlled by conventional therapy”, Endocrine Reviews, Endocrine Society's 96th Annual Meeting and Expo, Jun. 21-…
[cited by applicant]
Edmunds et al., “Effect of octreotide on gastric and small bowel motility in patients with gastroparesis,” Aliment Pharmacol. Ther. (1998) vol. 12, No. 2, pp. 167-174 (Abstract).
[cited by applicant]
European Office Action dated Dec. 16, 2011 for application No. 05 857 653.9-1219.6 pages.
[cited by applicant]
Extended European Search Report for Application No. 17742029.6, dated Sep. 10, 2019, 6 pages.
[cited by applicant]
Farthing, M.J.G., “Octreotide in dumping and short bowel syndromes,” Digestion (1993) vol. 54, Suppl. 1, pp. 47-52 (Abstract), 2 pages.
[cited by applicant]
Farthing. “Octreotide in the treatment of refractory diarrhoea and intestinal fistulae,” Gut 1994, Supplement 3, S5-S10 (1994). 6 pages.
[cited by applicant]
Fasano, et. al., “Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions” Proc. Nat. Acad. Sci. USA, 88: 5242-5246 (1991).
[cited by applicant]
Filikov, et. al., “Structure-based design of ligands for protein basic domains: application to the HIV-1 Tat protein”, J. Comput. Aided Mol. Des.12(3): 229-240 (1998).
[cited by applicant]
Fiorentini, et. al., “Clostridium difficile toxin A and its effects on cells.” Toxicon, 29(6): 543-567 (1991).
[cited by applicant]
Fox, “Developments in parathyroid hormone and related peptides as bone-formation agents”, Curr. Opin. Pharmacol., 2: 338-344 (2002).
[cited by applicant]
Fricker et al. “Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations” British Journal of Pharmacology (1996) vol. 117, pp. 217-223.
[cited by applicant]
“FSRH Guideline: Combined Hormonal Contraception”, The Faculty of Sexual & Reproductive Healthcare, 2019, pp. 1-108.
[cited by applicant]
Geer, Richard J. et al. “Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome.” Annals of Surgery 212.6 (1990): 678.
[cited by applicant]
Gillis et al., “Octreotide long-acting release (LAR),” Drugs (1997) vol. 53, No. 4, pp. 681-699.
[cited by applicant]
Giustina et al. “A consensus on the medical treatment of acromegaly” Nature Reviews Endocrinology (2014) vol. 10, pp. 243-248.
[cited by applicant]
Grasso et al., “Investigational therapies for acromegaly”, Expert Opinion on Investigational Drugs, (2013), 22: 8, pp. 955-963.
[cited by applicant]
Gumbiner, “Structure, biochemistry, and assembly of epithelial tight junctions.” Am. J. Physiol., 253: C749-C758 (1987).
[cited by applicant]
Hecht, et. al., “Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers.” J. Clin. Invest., 82: 1516-1524 (1988).
[cited by applicant]
Hemingway et al. “The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood now in an experimental model of hepatic metastases” Br. J. Cancer (1992) vol. 65, pp. 396-398.
[cited by applicant]
Higgins et al., “The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept,” J. Sex Res., 2016, 52(4-5): 417-456.
[cited by applicant]
Higham, C.E. et al., “Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial”, The Journal of Clinical Endocrinology & Metabolism, Jan. 25, 2012, vol…
[cited by applicant]
Hoeldtke, RD et al., “Treatment of Orthostatic Hypotension with Octreotide,” Journal of Clinical Endocrinology and Metabolism, The Endocrine Society, vol. 68, No. 6, Jun. 1989, pp. 1051-1059.
[cited by applicant]
Hsi-U I Ho et al., “Preparation of microemulsions using polyglycerol fatty acid esters as surfactant for the delivery of protein drugs”. Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washingto…
[cited by applicant]
Huffman, F.G., et al., “L-Glutamine Supplementation Improves Nelfinavir-Associated Diarrhea in HIV-Infected Individuals,” HIV clinical trials, Feb. 2, 2015, vol. 4(5), pp. 324-329.
[cited by applicant]
International Preliminary Report on Patentability from International Application Serial No. PCT/IB07/04569 issued Nov. 3, 2009, 6 pages.
[cited by applicant]
International Search Report and Written Opinion from international patent application No. PCT/IB07/04569, dated Oct. 20, 2009, 6 pages.
[cited by applicant]
International Search Report and Written Opinion from PCT Application No. PCT/US2015/065006, dated Feb. 23, 2016, 9 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for PCT/US2016/016384, mailed Apr. 22, 2016, 7 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for PCT/US2017/014379, mailed Apr. 7, 2017, 15 pages.
[cited by applicant]
International Search Report dated Mar. 18, 2010, in WO application—PCT/IB09/07155, 3 pages.
[cited by applicant]
International Search Report from international patent application No. PCT/IB2005/004183, dated Oct. 19, 2006, 8 pages.
[cited by applicant]
IOM (Institute of Medicine), A Review of the HHS Family Planning Program: Mission, Management, and Measurement of Results. Washington, DC: The National Academies Press. 2009, 1-487.
[cited by applicant]
Irving et al. “Therapeutic value of octreotide for patients with severe dumping syndrome—a review of randomised controlled trials.” Postgrad Med J, 2001, vol. 77, pp. 441-442 (2001).
[cited by applicant]
Isaacson, “Managed Care Approach to the Treatment of Neurogenic Orthostatic Hypotension,” The American Journal of Managed Care, Oct. 2015, pp. S258-S268. 11 pages.
[cited by applicant]
Jackson, “Drug Transport Across Gastrointestinal Epithelia”, Physiology of the Gastrointestinal Tract, 2nd Ed., Johnson, ed., Raven Press, New York, Chapter 59, 2: 1597-1621 (1987).
[cited by applicant]
Jansen et al., “Postprandial Hypotension: Epidemiology, Pathophysiology, and Clinical Management,” Annals of Internal Medicine, 1995, vol. 122, No. 4, pp. 286-295.
[cited by applicant]
Jenkins et al. “Pharmacokinetics of Octreotide in Patients with Cirrhosis and Portal Hypertension; Relationship Between the Plasma Levels of the Analogue and the Magnitude and Duration of the Reduction in Corrected Wedg…
[cited by applicant]
Jenkins et al. “Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage”, BMJ (1997) vol. 315, pp. 1338-1341.
[cited by applicant]
Jeppesen, P.B., et al., “Teduglutide, a Novel Glucagon-like Peptide 2 Analog, in the Treatment of Patients With Short Bowel Syndrome,” Therapeutic advances in gastroenterology, Feb. 15, 2012, vol. 5(3), pp. 159-171.
[cited by applicant]
Jiao, et. al., “In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits.” Circulation, 105: 230-235 (2002).
[cited by applicant]
Katznelson et al. “Acromegaly: an endocrine society clinical practice guideline.” Journal of Clinical Endocrinology and Metabolism (2014): vol. 99, No. 11, 3933-3951.
[cited by applicant]
Kohler, E. et al. “Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage.” European journal of clinical pharmacology 33.2 (1987): 167-171.
[cited by applicant]
Kulke, M.H., et al., “Telotristat Etiprate, a Novel Serotonin Synthesis Inhibitor, in Patients with—Carcinoid Syndrome and Diarrhea Not Adequately Controlled by Octreotide,” Endocrine Related Cancer, Oct. 2014, vol. 21(…
[cited by applicant]
Lancranjan, I. et al. “Sandostatin® LAR®: A Promising Therapeutic Tool in the Management of Acromegalic Patients,” Metabolism, 1996, 45(8): 1, 67-71.
[cited by applicant]
Lancranjan, I. et al. “Results of a European Multicentre Study with Sandostatin® LAR® in Agromegalic Patients” Pituitary 1999, 1: 105-114.
[cited by applicant]
Lariviere, W., et al., “Novel therapeutic approaches to autosomal dominant polycystic kidney disease,” Transl Res, 2015, 165(4): 488-98.
[cited by applicant]
Le Tourneau, Christophe, et al., “Dose escalation methods in phase 1 cancer clinical trials”, J Natl Cancer Inst, May 20, 2009; 101(10): 708-20, Epub May 12, 2009.
[cited by applicant]
Lin et al., “Haemodynamic effects of 8-day octreotide and prazosin administration in portal hypertensive rats.” European Journal of Clinical Investigation, 28 (8), 622-628. (1998). 1365-2362.
[cited by applicant]
Lueck, Christian J., and Gawn G. McIlwaine. “Interventions for idiopathic intracranial hypertension.” The Cochrane Library (2009). 14 pages.
[cited by applicant]
Lustig, R. H., et al. “A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.” In…
[cited by applicant]
Madara, “Loosening Tight Junctions: Lessons from the Intestine,” J Clin Invest, Apr. 1989; 83(4): 1089-1094.
[cited by applicant]
Madsen, M. et al., “Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients”, The Journal of Clinical Endocrinology & Metabolism, Jun. 1, 2011, vol. 96(8), pp. 2405-2413.
[cited by applicant]
Manjila et al. “Pharmacological management of acromegaly: a current perspective.” Neurological Focus (2010): vol. 29. No. 4, 1-9.
[cited by applicant]
Manning et al. “Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics,” Journal of Neuroendocrinology, 2012, 24: 609-628.
[cited by applicant]
McCormick, P. Aiden, et al. “Cardiovascular effects of octreotide in patients with hepatic cirrhosis.” Hepatology 21.5 (1995): 1255-1260.
[cited by applicant]
Melmed, Shlomo et al. “Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial” J. Clin. Endocrinol. Metab. 100.4 (2015):1699-1708. & Erratum to: “Safety and Efficacy of Oral Octre…
[cited by applicant]
Melmed, S. et al. “OR17-5: Efficacy and Safety of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial in 155 Patients” Abstracts—Orals, Poster Preview Presentations, and Posters, OR17-From Genetics t…
[cited by applicant]
Melmed, Shlomo. “New therapeutic agents for acromegaly.” Nature Reviews Endocrinology 12.2 (2016): 90-98; Advanced online publication Nature Reviews Endocrinology Nov. 27, 2015, pp. 1-9.
[cited by applicant]
Mimuro et al., “The somatostatin analogue, octreotide, modifies both steroidogenesis and IGFBP-1 secretion in human utenizing granulosa cells,” Human Reproduction, 1998, 13(1): 150-150.
[cited by applicant]
Moller, Soren, et al. “Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis.” Journal pf Hepatology 26.5 (1997): 1026-1033.
[cited by applicant]
Moreau et al. “Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study,” Gut, 2002, 50: 90-94.
[cited by applicant]
Moreland, “Rheumatology and Immunology Therapy: A-Z essentials,” (2004) Springer Science & Business Media, pp. 13.
[cited by applicant]
MYCAPSSA™ (Formerly Octreolin™) Efficacy and Safety of Octreotide for Acromegaly, History of Changes for Study: NCT01412424, 2017, U.S. National Library of Medicine, ClinicalTrials.gov, 16 pages.
[cited by applicant]
MYCAPSSSA® (octreotide) delayed-release capsules for oral use, Prescribing Information, Chiasma, 2020, pp. 1-17.
[cited by applicant]
Nardone et al., “The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract.” Aliment Pharmacology & Therapeutics, 13(11), pp. 1429-1436 (1999).
[cited by applicant]
Neggers, et al., “Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly”, J Clin Endocrinol Metab, Dec. 2007; 92(12): 4598-601.
[cited by applicant]
Neggers et at “Long-Term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.” Journal of Clinical Endocrinology and Metabolism (2014): vol. 99, No. 10, 3644-3652.
[cited by applicant]
Newman, C.B. et al., “Octreotide as Primary Therapy for Acromegaly”, J Clin Endocrinol MEtab, 83, pp. 3034-3040, 1998.
[cited by applicant]
Nir et al, “Fear of injections in young adults; prevalence and associations”, Am. J. Trop. Med. Hyg., 68(3), pp. 341-344 (2003).
[cited by applicant]
“Octreotide for a Possible Cure for IIH” Facebook; Retrieved from www.facebook.com/pages/Octreotide-for-a-possible-Cure-for-IIH, on Mar. 3, 2015. 5 pages.
[cited by applicant]
Ouyang, et. al., “Structure-activity relationship for enhancement of paracellular permeability across Caco-2 cell monolayers by 3-alkylamido-2-alkoxypropylphosphocholines.” J. Med. Chem.45(13): 2857-2866 (2002).
[cited by applicant]
Panagopoulos, G. N., et al. “Octreotide: a therapeutic option for idiopathic intracranial hypertension.” Neurol Neurophysiol Neurosci, 1 (2007): 1-6.
[cited by applicant]
Prescribing information for Sandostatin LAR Sep. 2011, Novartis, 17 pages.
[cited by applicant]
Rebouche, “Carnitine absorption: effects of sodium valproate and sodium actanoate in the caco-2 cell culture model of human intenstinal epithelium”, L. Nutr. Biochem., vol. 9, pp. 228-235 (Apr. 1998).
[cited by applicant]
Reid, Tirissa J. et al, fflgf-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivyt, markers of cardiovascular risk and body composition. Pituitary (2015) pp. 808-819.
[cited by applicant]
Ruggenenti et al., “Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polyscystic kidney disease,” Kidney International, vol. 68, 2005, pp. 206-216.
[cited by applicant]
Sanchez, George A., Nisa Kubiliun, and Jamie S. Barkin. “Variceal bleeding and long-acting octreotide: a new addition to the armamentarium?” Digestive diseases and sciences 53.11 (2008): 3046-3047.
[cited by applicant]
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, Prescribing Information, Novartis Pharmaceuticals Corporation, 2019, pp. 1-21.
[cited by applicant]
Sandostatin (octreotide acetate), Prescribing Information, as approved by the FDA; initial U.S. Approval 1988; Novartis; Retrieved from the Internet (URL):https://accessdata.fda.gov/drugsatfda_docs/abel/2010/019667s058,…
[cited by applicant]
Schilfgaarde, et. al., “Cloning of genes of nontypeable Haemophilus influenzae involved in penetration between human lung epithelial cells.” Infect. Immun.68(8): 4616-4623 (2000).
[cited by applicant]
Search Report for CN 200980140593.9 dated Mar. 12, 2013, 2 pages.
[cited by applicant]
Shimon et al. “Estrogen treatment for acromegaly.” Pituitary (2012): vol. 15, No. 4, 601-607.
[cited by applicant]
Spahr, Laurent, et al. RA 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study The American Journal of Gastroentero…
[cited by applicant]
Strasburer et al., “Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly” European Journal of Endocrinology, 2016, 174: 355-362.
[cited by applicant]
Suda et al. “Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.” Endocrine Journal (2013): vol. 60, No. 4, 507-515.
[cited by applicant]
Thanou, M., et al. “Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo.” Journal of pharmace…
[cited by applicant]
Thanou, Maya, et al. “Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs.” Pharmaceutical research 18 .6 (2001): 823-828.
[cited by applicant]
Tuvia, et al., “A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules via Transient and Reversible Transport Mechanisms”. Pharm Res. (Feb. 21, 2014); 31(8): 2010-2021.
[cited by applicant]
Tuvia, S., et al., “Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression,” The Journal of Clinical Endocrinology & Metabolism, Jul. …
[cited by applicant]
Vallette et al., “Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly?” Pituitary, 2010, 13: 311-314.
[cited by applicant]
Vance, M.L. et al., “Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide”, Arch Intern Med, 151, pp. 1573-1576, 1991.
[cited by applicant]
Vinken et al. “Fulminant eosinophilic myocarditis leading to sudden death in a young acromegalic woman”, Acta Clin Belg, Sep.-Oct. 2005; 60(5): 253-5.
[cited by applicant]
Vorobioff, Julio D., et al. “Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.” The American journal of gastroenterology 102.10 (2007): 2206-2213.
[cited by applicant]
Walpole et al., “The weight of nations: an estimation of adult human biomass,” BMC Public Health, 2012, vol. 12, p. 439.
[cited by applicant]
Wang, et. al., “Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo.” Am. J. Respir. Cell Mol. Biol., 22: 129-138 (2000).
[cited by applicant]
Watnasirichaikul, et. al., “In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion.” J. Pharm. Pharmacol., 54(4): 473-480 (2002).
[cited by applicant]
Watnasirichaikul S. et al, “Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions”, Pharmaceutical Research, vol. 17, No. 6, p. 684-689 (2000).
[cited by applicant]
Williams, G., et al. “Effective and lasting growth-hormone suppression in active acromegaly with oral administration pf somatostatin analogue SMS 201-995.” The Lancet 328.8510 (1986): 774-778.
[cited by applicant]
Wolf, David C. “The management of variceal bleeding: past, present and future.” The Mount Sinai journal of medicine, New York 66.1 (1999): 1-13.
[cited by applicant]
Wolin, E.M., et al., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Long-acting Release (LAR) Formulation of Pasireotide (SOM230) in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Result…
[cited by applicant]
Wright et al., “Fear of needles-nature and prevalence in general practice”, Australian family physician, 38(3) Mar. 2003.
[cited by applicant]
Written Opinion in International Application No. PCT/IB09/07155, dated Mar. 18, 2010, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for corresponding international patent application PCT/IB2005/004183, dated Oct. 19, 2006, 11 pages.
[cited by applicant]
Yowell, et. al., “Novel Effects with Polyethylene glycol modified pharmaceuticals”, Cancer Treat. Rev., 28(Suppl. A): 3-6 (2002). 5 pages.
[cited by applicant]
Zavoico, et al., “Perturbation of egg phosphatidylcholine and dipalmitoylphosphatidylcholine multilamellar vesicles by n-alkanols. A fluorescent probe study.” Biochimica et Biophysica Acta, 812(2): 299-312 (1985).
[cited by applicant]
Zidan, J., et al. “Octreotide in the treatment of severe chemotherapy-induced diarrhea.” Annals of oncology 12.2 (2001): 227-229.
[cited by applicant]
Alexopoulou et al., “Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR”, Eur J Endocrinol. Sep. 2004;151(3): 317-24. doi: 10.1530/eje.0.1510317.
[cited by applicant]
[Author Unknown] “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 Express)”, U.S. Department of Health and Human Services, National In…
[cited by applicant]